Drugs / HRX215
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06638502 | May 2025 → Jul 2027 expected | metastasis from malignant tumor of colon | HepaRegeniX GmbH | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRX215 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06638502 ↗ |
| Route | Oral | “HRX215 250 mg orally twice daily for a total treatment duration of 28 days” NCT06638502 ↗ |